Bioceres Reports Q1 2026 Financial Results
Bioceres (BIOX) reported a decline in total revenues for Q1 2026, primarily due to strategic deprioritization of lower-margin sales and segment timing effects. However, the company achieved significant cost reductions and improved gross margins across several segments.
